Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to announce the appointment of Mr John (Chris) Lawrence as a director to the TruScreen Board, effective from 21 December 2017.
Chris is a successful New Zealand businessman and a significant investor in life science and bio technology businesses. He is a significant investor in Truscreen and was a major contributor to the March 2017 capital raising.
Chairman of TruScreen, Mr Robert Hunter, commented: “We are fortunate to have Mr Lawrence join the Board. His business experience and alignment with shareholder and company objectives will be of value as we progress our commercial strategy.”
Mr Lawrence is ordinarily resident in New Zealand and has been appointed by the current TruScreen directors, as permitted under TruScreen’s constitution. He will hold office until TruScreen’s 2018 Annual Meeting at which time he will offer himself for election by shareholders.
For more information visit www.truscreen.com or contact:
TruScreen Chief Executive Officer
Phone: +64 27 246 2505
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.